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Abstract
The aim of this study was to analyze the distribution of FGFR3 mutations in bladder tumors of different grade and
stage and determine the relation of mutations to chromosomal alterations detected by comparative genomic hy-
bridization (CGH). One hundred bladder cancer samples served as templates for manual microdissection. DNA was
isolated from dissected samples containing at least 80% tumor cells. Mutations in FGFR3 were analyzed by SNaP-
shot analysis. CGH was carried out according to standard protocols. FGFR3 mutations were detected in 45 of 92
samples (48.9%). Concerning T-category, the following mutation frequencies occurred: pTa, 69%; pT1, 38%; and
pT2–3, 0%. The mutation frequency was significantly associated with tumor grade: G1, 72%; G2, 56%; and G3,
4%. In pTaG1 tumors, mutations were found in 74%. A significantly lower number of genetic alterations per tumor
detected by CGH was associated with FGFR3 mutations (2 vs 8). This association was also seen in pTaG1 tumors:
2.5 (with mutation) vs 7.5 (without mutation). FGFR3 mutations characterize noninvasive low-risk tumors of low
malignancy. The low malignant potential of these tumors is underlined by a low number of genetic alterations
per tumor. Therefore, FGFR3 represents a valuable prognostic marker of tumors with low malignant potential
and can be used as surrogate marker for the detection of genetically stable bladder tumors.
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Introduction
Urothelial carcinomas of the urinary bladder represent the fifth com-
mon cancer and 357,000 new cases are diagnosed every year world-
wide [1]. Most of these tumors are noninvasive well-differentiated
papillary tumors (pTa, low grade) and can be treated by endoscopical
transurethral resection. However, up to 70% of these tumors recur
and, of these, 15% to 30% are characterized by tumor progression.
An early detection of invasive tumors is necessary for an effective ther-
apy. Now, no prognostic parameters are available to predict the risk of
recurrence or progression for the patient. Therefore, new prognostic
markers are required for an individual prognosis of patients with blad-
der cancer. The knowledge of tumor biology and the identification of
genes and proteins involved in tumor development and progression are
essential for new diagnostic and prognostic tools.
Fibroblast growth factor receptor 3 (FGFR3) could represent a
promising biomarker for bladder cancer. FGFR3 is a glycoprotein
and belongs to the tyrosine kinase receptor family. Constitutive acti-
vation of FGFR3 by germline point mutations leads to congenital
anomalies such as achondroplasia and thanatophoric dysplasia
[2,3]. Recently, it has been shown that somatic mutations of the
FGFR3 gene occur frequently in urothelial tumors of the bladder
and less frequently in carcinomas of the cervix uteri, suggesting that
FGFR3 plays an oncogenic role [4]. Further studies demonstrated
that mutations in FGFR3 occur frequently in noninvasive urothelial
tumors of the bladder, but not in invasive tumors, and might corre-
late with favorable clinical outcome [5–7].
Abbreviations: CGH, comparative genomic hybridization; FGFR3, fibroblast growth
factor receptor 3; PCR, polymerase chain reaction
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In the last 10 years, it was clearly demonstrated that two different
pathways exist in the development of urothelial carcinomas [8]. Non-
invasive papillary tumors are genetically stable with few chromosomal
alterations and a low malignant potential with frequent recurrences but
very infrequent progression to invasive disease. In contrast, flat urothe-
lial lesions like dysplasia and carcinoma in situ are genetically unstable
with multiple chromosomal alterations and a rapid progression to in-
vasive highly malignant tumors with unfavorable outcome [9,10].
The aim of this study was to analyze both FGFR3 mutations and
chromosomal alterations of urothelial tumors of the bladder to inves-
tigate whether tumors with FGFR3 mutations are genetically more
stable than tumors without mutations. To our knowledge, this is
the first study investigating chromosome alterations over the whole
genome and FGFR3 mutation status in correlation with histopatho-
logical data in a large consecutive series.
Materials and Methods
One hundred primary consecutive urothelial carcinomas with dif-
ferent T-categories and grade were included in this study (Table 1).
Tumor samples were obtained immediately after transurethral resection
or radical cystectomy and were snap frozen in liquid nitrogen. Frozen
sections were done for all specimens and stained by hematoxylin–eosin
to define areas with high amount of tumor cells. Areas with at least 80%
tumor cells were manually microdissected and DNA was isolated with a
commercial kit (Qiagen, Hilden, Germany).
Informed consent was obtained from all patients. Histopathology
was assessed on the paraffin-embedded material of the patients by
one surgical pathologist. Grading was done according to the 1973
World Health Organization classification.
Mutation Analysis
Analysis of the FGFR3 gene for mutations was based on the ABI
PRISM SNaPshot Multiplex Kit (Applied Biosystems, Foster City,
CA), and performed as described previously [11]. In short, three re-
gions of interest comprising nine FGFR3 mutations were amplified
in one multiplex polymerase chain reaction (PCR), followed by ex-
tension of primers for each mutation with a labeled dideoxynucleo-
tide. Extended primers were separated by capillary electrophoresis,
and the presence or absence of a mutation was indicated by the in-
corporated nucleotide.
Comparative Genomic Hybridization
Comparative genomic hybridization (CGH) was performed in
cases where mutation analysis revealed a result. To obtain sufficient
amounts of DNA for CGH analysis, tumor DNA was amplified ac-
cording to a modified protocol for degenerate oligonucleotide-primed
PCR [12,13]. This protocol uses Sequenase (GE Healthcare, Munich,
Germany) during the first eight cycles of nonspecific PCR, followed
by 30 additional cycles under specific conditions using Taq poly-
merase (Stoffel fragment; Perkin Elmer, Rodgau-Jügesheim, Germany).
Labeling of tumor DNA and normal DNA was achieved by 20 PCR
cycles using biotin–16dUTP and digoxigenin–11dUTP, respectively.
One microgram of both tumor DNA and normal DNA were hy-
bridized with 50 μg Cot-1 DNA on normal metaphases at 37°C for
48 hours. Detection of fluorescent signals was carried out with avidin–
FITC (tumor DNA) and anti–digoxigenin–rhodoamine (normal
DNA). DAPI–Antifade (GE Healthcare) was used for chromosome
counterstaining. Fifteen metaphases were analyzed in each case using
a microscope (Axioplan 2; Carl Zeiss AG, Oberkochen, Germany) and
a computer system (MetaSystems, Altlussheim, Germany). Chromo-
somal alterations can be detected as shifts of the profile to the red bor-
derline (loss of chromosomal region in the tumor DNA) or to the
green borderline (gain of chromosomal region in the tumor DNA).
Statistical Analysis
Statistical analysis was performed using the Statistical Package for
the Social Sciences (SPSS Inc., Chicago, IL) software. The chi-square
and the Mann-Whitney U tests were used.
Results
Mutation Analysis
Mutation analysis was possible in 92 of 100 cases. FGFR3 muta-
tions were detected in 45 of 92 cases (48.9%). Mutations in codon
249 (S249C) occurred most frequently (25 cases). Codons 375
(Y375C), 372 (G372C), 248 (R248C), and 652 (K652E and
K652T) mutations were found in 10, 4, 3, and 3 cases, respectively
(see Table 2).
Correlation with stage. A strong correlation between mutations
and stage was found. Mutations occurred only in pTa (69%) and
pT1 tumors (38%), but never in higher stage tumors (pT2–3 0%,
see Figure 1). These results were statistically significant (P < .001).
Comparison of mutation frequency between pTa and pT1 tumors
was also significant (P = .013).
Correlation with grade. Mutations were detected mostly in G1
and G2 tumors, but only in one G3 tumor (see Figure 2). These
results were statistically significant (P < .001). Mutations occurred
in 72% of G1 and in 56% of G2 tumors (P = .227).
The mutation frequency was 74% in pTaG1 tumors and 54% in
pTaG2 tumors, respectively.
Comparative Genomic Hybridization
CGH was performed on the 92 cases where mutation analysis was
possible. Results were obtained in 90 cases. Alterations were detected
in 62 cases (69%) (see Table 2). The mean number of genetic altera-
tions per tumor was 6.4. The following genetic alterations were
found frequently: losses of chromosomes 9 (55%), 8p (29%), 6
(23%), 11p (23%), and 5q (20%), and gains of chromosomes 8q
(44%) and 1 (21%).
Correlation with stage. The mean number of aberrations per tumor
was 4.73, 7.86, and 9.11 in pTa, pT1, and pT2–4 tumors, respectively
(P = .026). The frequency of specific alterations was higher with higher
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Table 2. Results After Mutation Analysis and CGH Analysis.
Case No. pT G FGFR3 Mutation CGH Results
102 pT cis G C 0 0
95 pTa G1 0 dim(8p), enh(3p21qter,6p,7q31qter,8q,10p12pter,12q23qter)
149 pTa G1 0 0
155 pTa G1 0 0
156 pTa G1 0 0
168 pTa G1 0 0
194 pTa G1 0 dim(2q,3p14p23,6,8p,9,14,17p), enh(8q)
196 pTa G1 0 dim(9q), enh(8q)
430 pTa G1 0 0
582 pTa G1 0 dim(5q,6q,9p,14), enh(5,16q,20)
367 pTa G1 G372C dim(Y)
583 pTa G1 G372C dim(9q13q31)
172 pTa G1 K652E dim(8p,9p,17p,18q12q21)
373 pTa G1 K652T dim(6q13qter,9q,17p), enh(1q,3q26qter,6p12q13,7p15pter,8q23)
190 pTa G1 R248C dim(9)
366 pTa G1 R248C dim(3p13p24,5q12q21,6q16qter,8p12pter,9,10q21qter,17p), enh(1q24,2q14q34,17q)
590 pTa G1 R248C 0
15 pTa G1 S249C enh(1p,15q), dim(9,11p)
23 pTa G1 S249C 0
27 pTa G1 S249C dim(9q,Y), enh(8q)
70 pTa G1 S249C 0
144 pTa G1 S249C dim(9,16q21qter,17p13pter), enh(1q24q41)
153 pTa G1 S249C dim(9q22q33)
157 pTa G1 S249C 0
179 pTa G1 S249C 0
204 pTa G1 S249C 0
207 pTa G1 S249C dim(9q21qter)
214 pTa G1 S249C 0
365 pTa G1 S249C dim(9q), enh(10q24q25)
379 pTa G1 S249C 0
140 pTa G1 Y375C dim(9)
333 pTa G1 Y375C dim(Y)
371 pTa G1 Y375C 0
378 pTa G1 Y375C dim(3p12p24,2q,4p15pter,6p?,8p,9q,14q22qter,17p), enh(5q14q31,8q,13q21qter)
440 pTa G1 Y375C dim(9q)
588 pTa G1 Y375C dim(9), enh(11q14q22)
71 pTa G2 0 0
110 pTa G2 0
137 pTa G2 0 0
441 pTa G2 0 enh(3p21pter,3q,5q,8q,10q,16q,17q), dim(4,5q,6q,8p,9,11,12,18q), amp(11q13)
571 pTa G2 0 enh(6p,7p,8,20), amp(11q13)
573 pTa G2 0 enh(1q32qter,2q15q22,5q,7q,8q,11q,13q21qter,18p,20), dim(2q32qter,5q,6p21.2q22,7p11.2p21,9,11p,
14,18q,Y), amp(8p11.1p22)
580 pTa G2 G372C dim(Y)
13 pTa G2 S249C dim(9q,Xp), enh(14q23qter,17,20q)
372 pTa G2 S249C 0
577 pTa G2 S249C enh(1p,8q,15), dim(8p,9,11p)
584 pTa G2 S249C enh(1q,8,13)
574 pTa G2 Y375C 0
579 pTa G2 Y375C dim(9q,11), enh(7), amp(12q21q22)
587 pTa G3 S249C dim(9,10q24q25,11p)
195 pT1 G1 0 0
62 pT1 G2 0 dim(5q?,5q33qter,6q22,8p12pter,9,11p,17p12pter), enh(6p?,17q?,18q?,20p), amp(8q23)
109 pT1 G2 0 dim(4q,5q23qter,8p,9q,11p,Y), enh(3q,6,7p,8q,10p,12p,18p,21)
138 pT1 G2 0 0
161 pT1 G2 0 dim(8p), enh(8q)
183 pT1 G2 0 dim(2q31qter,4q,5p,5q23qter,6p11.1p21.3,8q23qter,9,10q,13q12q14,Y), enh(3q25qter,6q12q21,10p,
11p11.2q13,15q,16), amp(5p13q11), amp(7p14pter), amp(8)(q11.1q12), amp(12)(q14q21)
429 pT1 G2 0 0
591 pT1 G2 0 enh(5p,8p11.1p22,10p,18p)
96 pT1 G2 K652E enh(3,8)
4 pT1 G2 S249C dim(9q), enh(8q)
61 pT1 G2 S249C dim(9), enh(1q)
89 pT1 G2 S249C dim(5q32q34,7p,9), enh(7q,15q)
201 pT1 G2 S249C 0
215 pT1 G2 S249C dim(8p,9p,10q23qter?,11p,18q21q22), enh(2p,3q?,12q14q21)
382 pT1 G2 S249C dim(8p12q11.2)
581 pT1 G2 S249C dim(3p14pter,9q21qter)
300 pT1 G2 Y375C enh(7), dim(9q,Y)
576 pT1 G2 Y375C dim(2q33qter,11)
22 pT1 G3 0 dim(4q32.1qter,12q21qter), enh(1q21q31,2q,3p25pter,5p,18p)
106 pT1 G3 0 dim(8p,18q), enh(5p,8q21q23,17p,18p)
185 pT1 G3 0 enh(8q22qter,16,17q,20)
210 pT1 G3 0 enh(5p,6p,10p,11q13q23,13q,16p,17q), dim(5q,Y), amp(8q22)
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T-category for many chromosomes (see Figure 3). However, statistical
significance was reached only for loss of chromosome 5q and loss of
chromosome 9 (more frequent in lower T).
Correlation with FGFR3 mutations. For all tumors, the number
of aberrations per tumor is significantly higher in tumors without
mutations (median 8.0) compared to that with FGFR3 mutations
(median 2.0, P < .001). In pTa tumors, the number of alterations
per tumor differs significantly between tumors with (median 2.5)
and without (median 7.5) mutations, too (P = .006).
Analysis of specific chromosomes revealed significantly more gains
of chromosomes 8q (P < .001), 5p (P = .003), 10p (P = .006), and
11q (P = .021), as well as losses of chromosomes 8p (P = .043) and
5q (P = .002) in tumors lacking mutations (see Figure 4). Interest-
ingly, losses of chromosome 9 were, however, significantly more fre-
quent in tumors with mutations (P = .005).
In pTa tumors, the above-described alterations were also different
in tumors with or without mutations (see Figure 5). However, statis-
tical significance was reached for chromosomes 5q (P = .038), 6 (P =
.017), 8q (P = .004), and 11q (P = .009). Losses of chromosome 9
were similarly distributed in both groups.
Discussion
Despite of good therapy options and favorable outcome, a high re-
currence rate is a serious problem in noninvasive bladder tumors of
low malignancy. In addition, urothelial carcinomas with stromal inva-
sion (pT1) show a considerable risk of progression to muscle invasive
disease. Until now, no prognostic parameters are available to predict
the individual outcome of these patients. During the last years, molec-
ular investigations were performed to understand the tumor biology of
bladder cancer and thereby to identify genes and proteins that are in-
volved in tumor development and progression. Several genes that
could be of prognostic significance in bladder cancer were identified.
It was shown that an accumulation of p53 is an independent prognos-
tic predictor of recurrence-free and overall survival [14,15]. However,
some studies failed to show the relationship with outcome possibly
Case No. pT G FGFR3 Mutation CGH Results
225 pT1 G3 0 dim(5q?,9q?), enh(1p13q31)
575 pT1 G3 0 dim(5q,7q32qter,8p,Y), enh(2p,3q,4p,4q31q33,5p,6p,8q21q23,10p,11q14q23,13q21qter,18p)
585 pT1 G3 0 enh(2p,3,5p,7,8,9,10p,20), dim(1p,5q11.2q15,6q,9,10q,14,17p)
586 pT1 G3 0 dim(2q32qter,4q13q31.1,5q,8p,10q,11p,13,14q11.2q24,16q), enh(1q21q32,2p,5p,−5q,6p,7q,8q,
10p,11q,16p,17,20)
589 pT1 G3 0 dim(4q26qter,6q,8p,10q23qter,11p,14,17p,18q), enh(1q24qter,2p11.2p22,2q24q25,3p22pter,3q,
5p,6p,7p,7q35qter,8p11.2q11.2,8q23q24,9p,11q23qter,20)
60 pT2 G3 0 dim(2q32qter,5q,11p12pter,12p,Y), enh(3,5p,8q21.3q22.3,13q21.3qter,14q,20q)
135 pT2 G3 0 dim(2q14,2,4p,6q,8p12pter,11p,13q13q31.3,14q21qter,16p,18q), enh(1p31p1q32.2,3q,4q?,5p,7,
16q22.1qter,18p,20q), amp(8q23)
178 pT2 G3 0 dim(1p,2q36qter,5q,6q,8p,10q,18q), enh(1q,5p,6p22p24,9p,10p12pter,13q31qter,17q23.2qter,18p,20q)
223 pT2 G3 0 dim(8p,11q23qter,18q21qter?), enh(3q24qter,6p22pter,8q,9,11p?,18q,14q)
224 pT2 G3 0 dim(2q36qter,10q,11q22qter), enh(6p23pter)
228 pT2 G3 0 0
578 pT2 G3 0 0
311 pT2b G3 0 0
66 pT3a G3 0 dim(6q), enh(8q21.1qter,11q14.3qter)
101 pT3a G3 0 0
108 pT3a G3 0
143 pT3a G3 0 dim(6p22pter,17p), enh(3q25q26,8q,9p23pter)
139 pT3b G2 0 dim(4q31qter,9,15q22qter,17p,Y), enh(7), amp(10q22q23)
381 pT3b G3 0 dim(4p,5q11.2q23,8p,18q), enh(5p,8q,10q25qter,20)
181 pTx G2 G372C 0
Mutations are specified for each codon.
0, no alterations were detected; Dim, loss of chromosome region; Enh, gain of chromosome region.
Figure 1. Frequency of FGFR3 mutations concerning T-category.
Table 2. (continued )
Figure 2. Frequency of FGFR3 mutations concerning tumor grade.
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because of different protocols for immunohistochemistry or patient se-
lections [16]. Because of the rare occurrence of p53 mutations in
pTaG1 tumors, other prognostic factors are necessary to predict the
outcome of these patients.
FGFR3 mutations were recently detected in bladder cancer by sev-
eral groups and described to be associated with low recurrence and
progression rate [4,6]. Fibroblast growth factor receptors belong to
the tyrosine kinase receptor family. They regulate cellular processes,
such as cell growth, differentiation, and angiogenesis.
In our study, we found FGFR3 mutations in about 50% of all tu-
mors. There was a strong correlation with stage and grade. Mutations
were restricted to pTa and pT1 tumors with high or moderate differ-
entiation and never occurred in muscle-invasive tumors. Therefore,
FGFR3 mutations are associated with noninvasive low malignant tu-
mors or tumors with limited invasive potential. These results con-
firmed findings of other studies. Whereas the frequency in pTa
tumors was similar compared to these studies, the percentage of
pT1 tumors with mutations differs between the studies [5,6,17].
One reason might be the different number of cases that were inves-
tigated and a different distribution of tumor grade in these cases. If
there were many pT1G3 tumors included, the percentage of cases
with mutations was very low. This strong correlation with grade
was striking in all studies. The majority of mutations were found
in low malignant tumors, whereas mutations in G3 tumors were very
rare. These results from different studies underline that FGFR3 mu-
tations characterize tumors with favorable histological features. Fur-
thermore, in the study of van Rhijn et al. [5], it was shown that the
presence of an FGFR3 mutation is a strong indicator of superficial
bladder tumors with a favorable clinical outcome. Recently, Hernandez
et al. [7] found FGFR3 mutations to be associated with a higher
rate of recurrence but again with good clinical outcome. Previous
studies clearly showed that bladder cancer cases can be separated in
two distinct tumor entities: 1) genetically stable low malignant tu-
mors with few genetic alterations, i.e., mainly deletions of chromo-
some 9, and 2) genetically unstable highly malignant tumors with
multiple genomic aberrations.
Based on these findings, we hypothesized that tumors with and
without FGFR3 mutations were also characterized by different chro-
mosomal patterns. For that reason, we performed CGH, which al-
lows the detection of chromosomal losses and gains over the whole
genome. Mutation analysis and CGH were carried out on the same
material and were correlated. To our knowledge, this is the first study
that combines FGFR3 mutation analysis with a whole genome chro-
mosome analysis. The number of genetic alterations was significantly
higher in tumors without FGFR3 mutations. This clearly indicates
that tumors with mutations are genetically more stable than tumors
without mutations. To exclude that this correlation was due to the
higher percentage of high-grade tumors in the group of invasive tu-
mors, we analyzed the pTa tumors separately. Even in this group, a
strong correlation of FGFR3 mutations with low number of chromo-
somal alterations was found. Therefore, mutations in FGFR3 charac-
terize noninvasive low malignant tumors that are genetically stable.
Looking at specific chromosomes, we found that losses of 5q and 6
as well as gains of chromosomes 8q, 10p, and 11q were significantly
more frequent in tumors without mutations. A similar picture was
seen in pTa tumors; however, statistical significance was reached only
for chromosomes 6, 8q, and 11q. Losses on chromosome 5 in blad-
der cancer are known from other studies [18,19], in which losses of
the chromosome regions 5q22–q23 and 5q33–q34 were found to be
associated with tumor progression [19]. Gain of 8q and loss of 8p are
known genetic alterations that are associated with progression in
many solid tumors as well as in bladder cancer [20–22]. Interestingly,
deletions of chromosome region 8p12–22 were found to be associ-
ated with invasive papillary bladder cancers [23]. To exclude that the
statistical correlation between specific genetic alterations and FGFR3
mutation is based on a correlation between stage and genetic altera-
tions, we performed statistical analysis between T-category and each
chromosomal alteration. As a result, we could not find statistical sig-
Figure 3. Contribution of chromosomal alterations detected by
CGH concerning T-category. Statistical significance was reached
for loss of chromosome 5q between Ta and T1 and for loss of
chromosome 9 between Ta, T1, and T2–3.
Figure 4. Frequency of chromosomal alterations detected by CGH
in tumors with and without FGFR3 mutations. Statistical signifi-
cance was reached for all presented chromosomes.
Figure 5. Frequency of chromosomal alterations detected by CGH
in pTa tumors with and without FGFR3 mutations. Statistical sig-
nificance was reached for chromosomes 5q, 6, 8q, and 11q.
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nificance even if there was an accumulation of the above alterations
in invasive tumors. Because the correlation between FGFR3 wild-type
status and gains of 8q was shown, we can conclude that gain of 8q is a
specific feature of more aggressive tumors without FGFR3 mutations.
Another significant alteration was a gain on 11q. Most often, loss
on 11q was described as associated with bladder cancer, but we found
it only in three tumors. However, several groups detected an ampli-
fication in the region 11q13q23 [22,24]. In our cases, gains on 11q
occurred mostly as amplifications or gains of a restricted region be-
tween 11q13 and q23. This region contains oncogenes, such as
CCND1, FGF3, and FGF4 , which could be activated by amplifica-
tion [25]. Amplification of these genes is associated with stage and
survival in pT1 tumors [26].
Loss on chromosome 9 correlated with FGFR3 mutations in the
whole tumor group. However, this correlation is based on distribu-
tion of chromosome 9 losses in different stages. There is a strong
correlation between loss of chromosome 9 and stage (see Figure 3).
A higher number of chromosome 9 alterations in pTa tumors com-
pared to pT1 to pT4 tumors was also described by Richter et al. [27].
Losses on chromosome 9 are apparently typical features of noninva-
sive low malignant papillary tumors (see Figure 3). In pTa tumors,
loss of chromosome 9 is similarly distributed in tumors with and
without mutations. Therefore, a correlation of FGFR3 mutations
and chromosome 9 alterations does not exist in pTa tumors. Obvi-
ously, alterations of chromosome 9 precede FGFR3 mutations in pTa
tumors. This is underlined by the fact that losses on chromosome 9
occur earlier than FGFR3 mutations in hyperplasias [28].
The results of our study underline that different pathways of blad-
der cancer pathobiology exist with different genetic alterations. This
hypothesis was described by van Rhijn et al. and Bakkar et al.
[17,29,30]. The authors investigated FGFR3 mutations and expres-
sion of several markers correlated with invasive tumors, such as p53,
MIB-1, or p27. They found that overexpression of p53 and MIB-1 is
very rare in tumors with FGFR3 mutations. The presence of p53 and
FGFR3 mutations is mutually exclusive in bladder tumors. Further-
more, the combination of FGFR3 mutation and proliferation index
(MIB-1) gives the base of a molecular grading which correlates with
clinical course and outcome. From these studies and from the results
of the present investigation, two distinct pathways of bladder cancer
development can be hypothesized (Figure 6). The first more frequent
group of tumors has FGFR3 mutations, has no alterations in p53,
and has low proliferation. These papillary tumors have low malignancy
and possess a low recurrence rate and, if at all, only a minimal progres-
sion risk. The second group consists of highly malignant solid and
papillary tumors without FGFR3 mutations, but frequent p53 altera-
tions and high proliferation index. These tumors frequently recur and
have a considerable progression risk. Our results clearly support this
hypothesis. In addition to the described features, the second pathway
is characterized by genetic instability on the chromosome level and by
specific chromosomal alterations, such as gain of 8q, amplification on
11q, and loss of 5q. Furthermore, specific molecular expression signa-
tures for progressive and nonprogressive pTa/pT1 tumors were identi-
fied by Dyrskjot et al. [31]. They suggested that it would be possible to
identify patients with high risk of disease progression at an early stage
of disease. Combination of expression analysis and genome analysis,
such as CGH or Array-CGH, will improve the detection of altered
genes in bladder cancer [32,33].
The identification of molecular markers and the combined use for
a molecular grading will be helpful in the future to predict the prog-
nosis of bladder cancer patients at time of first diagnosis and to select
a specific therapy at an early time point. Furthermore, the reproduc-
ibility of molecular markers is superior to that of classical parameters
such as stage and grade. Because most studies on molecular markers,
such as FGFR3, p53, or specific chromosomal markers, were per-
formed on retrospective material, prospective studies are required
to evaluate the clinical relevance.
In conclusion, we have shown that FGFR3 represents a valuable
prognostic marker of tumors with low malignant potential and that
it can be used as a surrogate marker for the detection of genetically
stable bladder tumors.
Figure 6. Scheme of different pathways in bladder cancer development.
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